Sinha Vikas 4/A
4/A · Verona Pharma plc · Filed May 22, 2025
Insider Transaction Report
Form 4/AAmended
Sinha Vikas
Director
Transactions
- Exercise/Conversion
Share Options (Right to Buy)
2025-04-29−120,384→ 0 totalExercise: $1.70Exp: 2027-04-26→ Ordinary Shares (120,384 underlying) - Sale
Ordinary Shares
2025-04-29$8.92/sh−39,616$353,406→ 74,440 total - Sale
Ordinary Shares
2025-04-29$8.92/sh−120,384$1,073,922→ 74,440 total - Exercise/Conversion
Ordinary Shares
2025-04-29$0.50/sh+39,616$19,959→ 114,056 total - Exercise/Conversion
Share Options (Right to Buy)
2025-04-29−39,616→ 160,384 totalExercise: $0.50Exp: 2032-04-27→ Ordinary Shares (39,616 underlying) - Exercise/Conversion
Ordinary Shares
2025-04-29$1.70/sh+120,384$204,653→ 194,824 total
Footnotes (6)
- [F1]This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.
- [F2]Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.
- [F3]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.
- [F4]Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.
- [F5]The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.
- [F6]The option is fully vested.